In yesterday’s Wall Street session, Blueprint Medicines Corporation (NASDAQ:BPMC) shares traded at $54.30, down -15.34% from the previous session.
As of this writing, 19 analysts cover Blueprint Medicines Corporation (NASDAQ:BPMC). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $114.00 and a low of $42.00, we find $80.00. Given the previous closing price of $64.14, this indicates a potential upside of 24.73 percent. BPMC stock price is now -9.04% away from the 50-day moving average and 9.04% away from the 200-day moving average. The market capitalization of the company currently stands at $3.11B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 4 analysts who have given it a hold rating, whereas 12 have given it a buy rating. Brokers who have rated the stock have averaged $74.65 as their price target over the next twelve months.
With the price target enhanced from $55 to $82, Wells Fargo Upgraded its rating from Equal Weight to Overweight for Blueprint Medicines Corporation (NASDAQ: BPMC).
In other news, Carter Percy H., CHIEF SCIENTIFIC OFFICER sold 2,307 shares of the company’s stock on Jun 05. The stock was sold for $120,102 at an average price of $52.06. Upon completion of the transaction, the CHIEF SCIENTIFIC OFFICER now directly owns 38,117 shares in the company, valued at $2.07 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 05, CHIEF MEDICAL OFFICER Hewes L. Becker sold 1,404 shares of the business’s stock. A total of $73,078 was realized by selling the stock at an average price of $52.05. This leaves the insider owning 36,878 shares of the company worth $2.0 million. Insiders disposed of 115,600 shares of company stock worth roughly $6.28 million over the past 1 year. A total of 1.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BPMC stock. A new stake in Blueprint Medicines Corporation shares was purchased by BAKER BROS. ADVISORS LP during the first quarter worth $18,118,000. JACOBS LEVY EQUITY MANAGEMENT, INC invested $6,888,000 in shares of BPMC during the first quarter. In the first quarter, SCHONFELD STRATEGIC ADVISORS LLC acquired a new stake in Blueprint Medicines Corporation valued at approximately $3,781,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in BPMC for approximately $2,245,000. HARBOR CAPITAL ADVISORS, INC. purchased a new stake in BPMC valued at around $1,322,000 in the second quarter.
Wednesday morning saw Blueprint Medicines Corporation (NASDAQ: BPMC) opened at $59.31. During the past 12 months, Blueprint Medicines Corporation has had a low of $37.82 and a high of $79.40. As of last week, the company has a debt-to-equity ratio of 0.34, a current ratio of 5.20, and a quick ratio of 5.10. The fifty day moving average price for BPMC is $59.69 and a two-hundred day moving average price translates $49.81 for the stock.
According to the Biotechnology Company, earnings per share came in at -$2.15, beating analysts’ expectations of -$2.67 by 0.52. This compares to -$1.79 EPS in the same period last year. The company reported revenue of $63.29 million for the quarter, compared to $62.73 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.89 percent. For the current quarter, analysts expect BPMC to generate $45.47M in revenue.
